CLX:NYSEClorox Company (The) Analysis

The stock is trading above its short‑term moving average but remains below the medium‑ and long‑term averages, signaling a bearish alignment despite a neutral RSI and a bullish MACD histogram. Volume has been slipping and 30‑day volatility is elevated, while beta is low, underscoring the defensive nature of the business but also hinting at limited upside momentum.
Fundamentally, revenue growth has stalled and the balance sheet is strained by a debt load that dwarfs equity, resulting in a negative book value and a high payout ratio that raises questions about dividend durability. Margins are solid and the dividend yield sits in the mid‑single digits, which is attractive in a consumer‑defensive sector, yet a recent governance probe adds a layer of regulatory uncertainty. The market price sits modestly below analyst median targets, suggesting a slight pricing discount but the overall risk profile remains mixed.